Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922932 · ClinicalTrials.gov registry record
WF and PR OCTA in Diabetic Retinopathy
A clinical trial of Diabetic Retinopathy, sponsored by Oregon Health and Science University.
- Active
- Registry status
- 290
- Enrollment target
- 1
- Study location
NCT03922932: Active study of Diabetic Retinopathy, sponsored by Oregon Health and Science University.
NCT03922932 is a study of Diabetic Retinopathy that is active but no longer recruiting, run by Oregon Health and Science University. The registered enrollment target is 290 participants, below the 1,671-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03922932, a study of Diabetic Retinopathy, is active but no longer recruiting, sponsored by Oregon Health and Science University.
- ACTIVE NOT RECRUITING
- Registry status
- 290 participants
- Enrollment target
- 1
- Study location
Study Summary
Diabetic retinopathy (DR) is a leading cause of vision loss in working-age Americans. Capillary damage from hyperglycemia causes vision loss through downstream effects, such as retinal ischemia, edema, and neovascularization (NV). Proper screening and timely treatment with laser photocoagulation and anti-vascular endothelial growth factor (VEGF) injections can minimize morbidity. In the last decade, clinicians have been able to use objective structural data from optical coherence tomography (OCT) to guide the treatment of diabetic macular edema. Other aspects of care, however, still largely depend on subjective interpretation of clinical features and fluorescein angiography (FA) to determine the disease severity and treatment threshold. The recently developed OCT angiography (OCTA) provides dye-less, injection-free, three-dimensional images of the retinal and choroidal circulation with high capillary contrast. Not only is it safer, faster, and less expensive than conventional dye-based angiography, OCTA provides the potential of giving clinicians objective tools for determining severity of disease by detecting and quantifying NV and non-perfusion.
Primary Outcome
Non-perfusion areas of the 3 retinal plexuses and choriocapillaris will be measured in mm2.
Conditions Studied
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2017-08-30 |
| Est. Completion | 2027-12 |
What the registry record for NCT03922932 still lists
NCT03922932 is an observational study that tracks outcomes without assigning an intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap, below the 1,671-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 0 interventions.
NCT03922932 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT03922932 about?
NCT03922932 is a clinical study titled "WF and PR OCTA in Diabetic Retinopathy". Diabetic retinopathy (DR) is a leading cause of vision loss in working-age Americans. Capillary damage from hyperglycemia causes vision loss through downstream effects, such as retinal ischemia, edema, and neovascularization (NV). Proper screening and timely treatment with laser photocoagulation and...
What is the current status of trial NCT03922932?
This trial is currently active not recruiting. The enrollment target is 290 participants. The study started on 2017-08-30. Estimated completion is 2027-12.
What conditions does trial NCT03922932 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
Who is sponsoring clinical trial NCT03922932?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03922932 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03922932's enrollment target sits among peer trials
290 23rd of 57 higher than 35 of 57 other Diabetic Retinopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Retinopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
RECRUITING
-
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
RECRUITING · NA
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
-
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI